JYQ-42

JYQ-42
Clinical data
Drug class	Sirtuin-6 (SIRT6) inhibitor
Identifiers
	IUPAC name 1-(4-amino-1,2,5-oxadiazol-3-yl)-N-[(E)-[3-chloro-5-(trifluoromethyl)phenyl]methylideneamino]triazole-4-carboxamide;
CAS Number	2838025-41-3 ;
PubChem CID	175602516 ;
Chemical and physical data
Formula	C13H8ClF3N8O2
Molar mass	400.71 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1=C(C=C(C=C1C(F)(F)F)Cl)/C=N/NC(=O)C2=CN(N=N2)C3=NON=C3N;
	InChI InChI=1S/C13H8ClF3N8O2/c14-8-2-6(1-7(3-8)13(15,16)17)4-19-21-12(26)9-5-25(24-20-9)11-10(18)22-27-23-11/h1-5H,(H2,18,22)(H,21,26)/b19-4+; Key:YUEMOICLRSWFIT-RMOCHZDMSA-N;

Last updated September 14, 2025

JYQ-42 is a drug which acts as a sirtuin-6 (SIRT6) inhibitor. It has potential applications in cancer treatment, having been found to inhibit the migration of pancreatic cancer cells and thereby reduce tumor invasiveness.^[1]^[2]

References

↑ Zhang Q, Chen Y, Ni D, Huang Z, Wei J, Feng L, et al. (2022). "Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells". Acta Pharmaceutica Sinica B. 12 (2): 876–889. doi:10.1016/j.apsb.2021.06.015. PMC 8897208 . PMID 35256952.
↑ Chouhan S, Kumar A, Muhammad N, Usmani D, Khan TH (2024). "Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications". Cancers. 16 (23): 4095. doi: 10.3390/cancers16234095 . PMC 11640239 . PMID 39682281.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Zhang Q, Chen Y, Ni D, Huang Z, Wei J, Feng L, et al. (2022). "Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells". Acta Pharmaceutica Sinica B. 12 (2): 876–889. doi:10.1016/j.apsb.2021.06.015. PMC 8897208 . PMID 35256952.

[2] Chouhan S, Kumar A, Muhammad N, Usmani D, Khan TH (2024). "Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications". Cancers. 16 (23): 4095. doi: 10.3390/cancers16234095 . PMC 11640239 . PMID 39682281.

[1]

[2]